SOURCE: The Mezey Howarth Group, Inc.

May 14, 2007 15:03 ET

Mezey Howarth Identifies Potential Targets for GeneThera

COSTA MESA, CA -- (MARKET WIRE) -- May 14, 2007 -- The Mezey Howarth Group announced that it has concluded its initial review of acquisition targets for GeneThera, Inc. (OTCBB: GTHA). Mezey Howarth has identified possible acquisition targets for GeneThera. GeneThera has retained Mezey Howarth to investigate possible strategic acquisitions in the health care field and/or biotech field.

"We are excited to have identified a number of possible acquisitions for GeneThera," said J. Wade Mezey of The Mezey Howarth Group. "We need to review the different possibilities with GeneThera and determine which one, if any, is the best fit for GeneThera."

"A combination means accelerated growth for GeneThera, and broader horizons for its shareholders," said Paul Howarth, of The Mezey Howarth Group. "We need to sit down with GeneThera and discuss each of the possible acquisition targets. We look forward to initiating discussions with the acquisition targets."

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.